All In Biotech

Drug Trial Radar · NCT00143611

Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

A Pivotal, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety of TAK-242 in Adults With Severe Sepsis

Last checked: Nov 20, 2026Latest source record: Feb 2, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Title says "pivotal". Randomized with 277 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

277

Actual

Start

Sep 2005

Primary completion

Feb 2007

Study completion Feb 2007

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 2, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the optimal dose of Resatorvid for reducing 28-day all-cause mortality in subjects with severe sepsis.

Conditions

  • Sepsis

Interventions

  • ResatorvidDrug

    Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.

  • ResatorvidDrug

    Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.

  • PlaceboDrug

    Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 28-day All-cause Mortality.Time frame: Day 28

Locations

144 sites in 17 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Escondido, California

  • Site not named

    Los Angeles, California

  • Site not named

    Orange, California

  • Site not named

    Poway, California

  • Site not named

    San Diego, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    New Haven, Connecticut

  • Site not named

    Newark, Delaware

  • Site not named

    Atlantis, Florida

  • Site not named

    Bay Pines, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Augusta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Peoria, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Des Moines, Iowa

  • Site not named

    Louisville, Kentucky

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Portland, Maine

  • Site not named

    Baltimore, Maryland

  • Site not named

    Springfield, Massachusetts

  • Site not named

    Kalamazoo, Michigan

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Butte, Montana

  • Site not named

    Englewood, New Jersey

  • Site not named

    Buffalo, New York

  • Site not named

    New York, New York

  • Site not named

    Rochester, New York

  • Site not named

    Greensboro, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Akron, Ohio

Showing 40 of 144 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.